CSF3 and neutropenia: Nonetheless, understanding G-CSF structure, expression, and mechanism of action on neutrophils may contribute to the development of a safe long-acting G-CSF therapy for patients with neutropenia that maintains the pharmacodynamic and pharmacokinetic of pegfilgrastim (Neulasta), but with more competitive manufacturing and lower unit costs compared with Neulasta (the cost for Neulasta is $6,417.99* per dose as of 18 August 2021).